Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00447122 · ClinicalTrials.gov registry record · Phase 1

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer

A Phase 1 study, sponsored by Brown University.

Terminated
Registry status
Phase 1
Development phase
25
Enrollment target

NCT00447122: Clinical Trial Phase 1 study, sponsored by Brown University.

NCT00447122 is a Phase 1 study that was terminated before completion, run by Brown University. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00447122, a Phase 1 study, was terminated before completion, sponsored by Brown University.

TERMINATED
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.

Interventions

  • DRUG Gemcitabine 1000mg/m2 30 minutes
  • DRUG Lapatinib 1000mg/d
  • DRUG Lapatinib 1500mg/d
  • DRUG Gemcitabine 1000mg/m2 100minutes
  • DRUG Oxaliplatin 100mg/m2

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2007-03
Est. Completion 2008-08
Phase Phase 1
Brown University

231 total trials

Why NCT00447122 stopped before completion

NCT00447122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 5 interventions - of which Gemcitabine 1000mg/m2 30 minutes is the first listed.

NCT00447122 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00447122 about?

NCT00447122 is a clinical study titled "BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer". Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.

What is the current status of trial NCT00447122?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-03. Estimated completion is 2008-08.

What interventions are being tested in trial NCT00447122?

The interventions under investigation include: Gemcitabine 1000mg/m2 30 minutes (DRUG), Lapatinib 1000mg/d (DRUG), Lapatinib 1500mg/d (DRUG), Gemcitabine 1000mg/m2 100minutes (DRUG), Oxaliplatin 100mg/m2 (DRUG).

Who is sponsoring clinical trial NCT00447122?

This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00447122's enrollment target sits among peer trials

25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00447122, the US trial registry maintained by the National Library of Medicine. NCT00447122 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.